Cohort1: ICT biopsy_Tcm
|
Administration route |
None |
Dosage |
2E6 cells, 10E6 cells |
Donor type |
Autologous |
Pts |
2 |
Age |
Child, Adult, Older_Adult |
References |
PMID:
38454126
|
|
Cohort2: ICT resection_Tcm
|
Administration route |
None |
Dosage |
2E6 cells, 10E6 cells, 50E6 cells, 20E6 cells, 100E6 cells |
Donor type |
Autologous |
Pts |
18 |
Age |
Child, Adult, Older_Adult |
References |
PMID:
38454126
|
|
Cohort3: ICV_Tcm
|
Administration route |
None |
Dosage |
2E6 cells, 10E6 cells, 50E6 cells, 20E6 cells, 100E6 cells |
Donor type |
Autologous |
Pts |
11 |
Age |
Child, Adult, Older_Adult |
References |
PMID:
38454126
|
|
Cohort4: dual ICT/ICV_Tcm
|
Administration route |
None |
Dosage |
2E6 cells, 10E6 cells, 50E6 cells |
Donor type |
Autologous |
Pts |
12 |
Age |
Child, Adult, Older_Adult |
References |
PMID:
38454126
|
|
Cohort5: dual ICT/ICV_Tn/mem
|
Administration route |
None |
Dosage |
2E6 cells, 10E6 cells, 50E6 cells, 20E6 cells, 100E6 cells |
Donor type |
Autologous |
Pts |
22 |
Age |
Child, Adult, Older_Adult |
Outcome |
1/21(CR); 10/21(SD); 10/21(PD); Median overall survival:10.2 months |
References |
PMID:
38454126
|
|